share_log

2023年度報告

ANNUAL REPORT 2023

Hong Kong Stock Exchange ·  Apr 29 06:39
Summary by Moomoo AI
微創醫療科學有限公司已發布截至2023年12月31日的年度報告及企業管治報告。該報告由畢馬威會計師事務所審計，依據香港財務報告準則反映公司財務狀況及績效。公司當年度錄得649.2百萬美元淨虧損，經營活動淨現金流出231.9百萬美元。報告指出，由於2024年到期的可轉換債券需償還448百萬美元，以及短期應付利息的借款295.4百萬美元，公司面臨重大的持續經營不確定性。年報亦提到，公司收入確認為關鍵審計事項，特別是關於基於數量向客戶提供的銷售回扣，以及在某些業務安排中對多項履約義務的交易價格分配。董事會由九名成員組成，包括一名執行董事、五名非執行董事和三名獨立非執行董事，由董事長兼首席執行官趙柱博...展開全部
微創醫療科學有限公司已發布截至2023年12月31日的年度報告及企業管治報告。該報告由畢馬威會計師事務所審計，依據香港財務報告準則反映公司財務狀況及績效。公司當年度錄得649.2百萬美元淨虧損，經營活動淨現金流出231.9百萬美元。報告指出，由於2024年到期的可轉換債券需償還448百萬美元，以及短期應付利息的借款295.4百萬美元，公司面臨重大的持續經營不確定性。年報亦提到，公司收入確認為關鍵審計事項，特別是關於基於數量向客戶提供的銷售回扣，以及在某些業務安排中對多項履約義務的交易價格分配。董事會由九名成員組成，包括一名執行董事、五名非執行董事和三名獨立非執行董事，由董事長兼首席執行官趙柱博士擔任。公司採納了針對董事和合資格員工的激勵計劃，如股份選擇計劃和股份獎勵計劃。在企業管治方面，公司遵循企業管治守則，唯獨董事長與首席執行官的合併角色不符。公司設有內部審計部門，獨立評估風險並審查風險管理和內部控制系統的有效性。此外，公司致力於與股東的開放溝通，並建立了股東溝通政策。公司股份在香港交易所上市，遵守相關上市規則及條例。
Micro-Chung Medical Sciences Limited has published its Annual Report and Corporate Governance Report for the year ended 31 December 2023. THE REPORT IS AUDITED BY THE FIRM OF PYRAMAWI ACCOUNTANTS AND REFLECTS THE FINANCIAL SITUATION AND PERFORMANCE OF THE COMPANY IN ACCORDANCE WITH THE HONG KONG FINANCIAL REPORTING CRITERIA. The company recorded a net loss of $649.2 million for the year and net cash outflow from operating activities of $231.9 million. The report noted that the company faces significant ongoing uncertainty due to $448 million in repayment of convertible bonds maturing in 2024 and $295.4 million in short-term interest borrowings. The Annual Report also mentions that the Company's revenue recognition is critical to audit matters, in particular regarding sales rebates provided to customers based...Show More
Micro-Chung Medical Sciences Limited has published its Annual Report and Corporate Governance Report for the year ended 31 December 2023. THE REPORT IS AUDITED BY THE FIRM OF PYRAMAWI ACCOUNTANTS AND REFLECTS THE FINANCIAL SITUATION AND PERFORMANCE OF THE COMPANY IN ACCORDANCE WITH THE HONG KONG FINANCIAL REPORTING CRITERIA. The company recorded a net loss of $649.2 million for the year and net cash outflow from operating activities of $231.9 million. The report noted that the company faces significant ongoing uncertainty due to $448 million in repayment of convertible bonds maturing in 2024 and $295.4 million in short-term interest borrowings. The Annual Report also mentions that the Company's revenue recognition is critical to audit matters, in particular regarding sales rebates provided to customers based on quantity and the allocation of transaction prices for multiple performance obligations in certain business arrangements. The Board of Directors consists of nine members, including one Executive Director, five Non-Executive Directors and three Independent Non-Executive Directors, headed by Dr. Zhu Zhu, Chairman and Chief Executive Officer. The company has implemented incentive programs for directors and eligible employees, such as the stock selection program and the stock reward program. In terms of corporate governance, the company follows the Corporate Governance Code, and only the combined roles of Chairman and CEO do not match. The company has an internal audit department that independently evaluates risks and reviews the effectiveness of risk management and internal control systems. In addition, the company is committed to open communication with shareholders and has established a shareholder communication policy. The company's shares are listed on the Hong Kong Stock Exchange in compliance with the relevant listing rules and regulations.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more